Ozempic and Metformin Together: Clinical Evidence, NICE Guidance, and Practical Advice

NICE NG 28 recommends metformin as the first medicine for type 2 diabetes. Sometimes metformin on its own does not control blood sugar well enough.

This usually means an HbA1c above 58 mmol/mol after 3 to 6 months. At that point, a second medicine is added.

GLP-1 receptor agonists, such as Ozempic, are one option at this stage. They are combined with metformin because the two drugs work in different ways.

What metformin mainly does:

• Lowers the amount of glucose the liver makes (the main cause of high fasting blood sugar)
• Helps muscle and fat tissue respond better to insulin
• Slightly reduces how much glucose the gut absorbs
• Has little effect on weight or causes mild loss (usually 1 to 2 kg)

What Ozempic mainly does:

• Boosts insulin release from beta-cells, but only when blood sugar is high
• Lowers glucagon (a hormone that raises blood sugar) when blood sugar is high
• Slows how fast the stomach empties, which reduces blood sugar spikes after meals
• Acts on the brain to reduce appetite, leading to clear weight loss

Metformin and semaglutide target different pathways. So their effects on blood sugar add up. In the SUSTAIN 2 trial, semaglutide 1 mg added to metformin lowered HbA1c by 16 mmol/mol (1.6%).

Sitagliptin in the same setting lowered it by only 7 mmol/mol (0.5%).

Several SUSTAIN trials tested semaglutide in patients already taking metformin. This gives us strong evidence for the combination.

SUSTAIN 2 (semaglutide vs sitagliptin, both added to metformin):

• 1,231 patients on a stable metformin dose (1,500 mg or more daily)
• 56-week study
• Semaglutide 1 mg: HbA1c fell by 16 mmol/mol (1.6%), with 6.1 kg weight loss
• Sitagliptin 100 mg: HbA1c fell by 7 mmol/mol (0.5%), with 1.9 kg weight loss
• Semaglutide did better on both measures

SUSTAIN 7 (semaglutide vs dulaglutide, both added to metformin):

• 1,201 patients on metformin
• 40-week study
• Semaglutide 1 mg: HbA1c fell by 18 mmol/mol (1.8%), with 6.5 kg weight loss
• Dulaglutide 1.5 mg: HbA1c fell by 14 mmol/mol (1.4%), with 3.0 kg weight loss

SUSTAIN 3 (semaglutide vs exenatide ER, added to metformin with or without a sulfonylurea):

• Semaglutide 1 mg: HbA1c fell by 15 mmol/mol (1.5%), with 5.6 kg weight loss
• Exenatide ER 2 mg: HbA1c fell by 9 mmol/mol (0.9%), with 1.9 kg weight loss

Across all these trials, metformin with semaglutide gave steady improvements. It lowered both blood sugar and body weight, and it had a good safety record.

Both metformin and Ozempic can upset the stomach and gut. When you take them together, these effects may overlap. This is most likely when you first start Ozempic.

Metformin gut effects:

• Diarrhoea (the most common), nausea, stomach discomfort, and a metallic taste
• Usually worst when you start or raise the dose
• Modified-release (MR) metformin causes fewer gut effects than immediate-release tablets

Ozempic gut effects:

• Nausea (up to 20%), vomiting, diarrhoea, and constipation
• At their worst while the dose is being raised (weeks 1 to 8)

Practical ways to handle the overlap:

• If you take immediate-release metformin and have bad gut symptoms, consider switching to modified-release before adding Ozempic
• Make sure your metformin dose is steady and well tolerated for at least 4 weeks before you start Ozempic
• Follow the full Ozempic dose schedule (0.25 mg for 4 weeks, then 0.5 mg). Do not skip steps
• Space out the timing if you take both around meals. Take metformin with food. You can inject Ozempic at any time
• Lowering the metformin dose for a while (for example, from 2,000 mg to 1,500 mg) during the first 4 weeks of Ozempic may help. You can raise it again once symptoms settle

In the SUSTAIN trials, adding semaglutide to metformin did not raise gut side effects much above semaglutide alone. This suggests the combination is well tolerated in practice.

A big benefit of the Ozempic and metformin combination is the low risk of hypoglycaemia (low blood sugar). Neither drug forces insulin out regardless of blood sugar levels.

Metformin and low blood sugar:

Metformin on its own does not cause low blood sugar. It does not directly trigger insulin release. The BNF says the risk with metformin alone is negligible.

Ozempic and low blood sugar:

Semaglutide only boosts insulin when blood sugar is high. This effect switches off when blood sugar drops below about 4 to 5 mmol/L. Low blood sugar is uncommon with Ozempic alone.

Combined risk:

The SUSTAIN trial data show that low blood sugar rates with semaglutide plus metformin are similar to placebo plus metformin. Serious low blood sugar (below 3.

1 mmol/L) happened in fewer than 1% of patients on this combination.

When the risk goes up:

• Adding a sulfonylurea (such as gliclazide). NICE NG 28 says to cut the sulfonylurea dose by 50% when you add a GLP-1 agonist
• Adding insulin. Review the basal insulin dose and usually reduce it by 10 to 20% when Ozempic starts
• Skipping meals while Ozempic reduces appetite. Patients should be advised to eat regular meals even when they feel less hungry

You do not need to check your blood sugar at home for the Ozempic and metformin combination, unless other medicines that lower blood sugar are also prescribed.

It helps to see where the Ozempic and metformin combination fits in the NICE plan. This shows patients why their prescriber chose it.

First-line:

Metformin on its own, raised to the highest dose you can tolerate (usually 2,000 mg daily). Lifestyle changes happen at the same time.

Second-line (HbA1c above 58 mmol/mol after 3 to 6 months on metformin):

NICE says to pick from several add-on options based on the individual patient:

• GLP-1 receptor agonist (Ozempic, Trulicity, Victoza): preferred when weight loss matters or BMI is 35 or more
• SGLT2 inhibitor (dapagliflozin, empagliflozin): preferred when heart failure or chronic kidney disease (CKD) is present
• DPP-4 inhibitor (sitagliptin, linagliptin): considered when weight should stay stable and cost matters
• Sulfonylurea (gliclazide): works well, but it can cause weight gain and low blood sugar

Why GLP-1 agonists are chosen more often:

• Proven heart benefit (SUSTAIN 6 data)
• Clear weight loss alongside better blood sugar control
• Low risk of low blood sugar
• Once-weekly dosing makes it easier to keep up than daily or twice-daily options

NICE rules for prescribing a GLP-1:

NICE used to limit GLP-1 agonists to patients with a BMI of 35 or more (or 30 or more with certain criteria). Newer guidance has eased these limits and looks at the benefit for each patient.

Your prescriber will weigh up your heart risk, your weight changes, and your blood sugar needs before suggesting this combination.

A clear daily and weekly routine helps when you take Ozempic and metformin together. It gets the most from both drugs and keeps side effects low.

Daily metformin routine:

• Take metformin with meals to reduce gut side effects
• If you take modified-release, take the full dose with your evening meal
• If you take immediate-release, split the dose across 2 to 3 meals
• Do not crush modified-release tablets

Weekly Ozempic routine:

• Pick the same day each week
• Inject at any time of day, with or without food
• Change injection sites (abdomen, thigh, upper arm)
• Keep the pen you are using at room temperature (below 30 degrees C) or in a fridge

Monitoring schedule:

• HbA1c at 3 months after starting Ozempic, then every 6 months
• Kidney function (eGFR) once a year, or more often if eGFR is below 60
• Vitamin B12 levels: metformin can lower B12 absorption over time. Check B12 if signs of low B12 appear (nerve pain, tiredness, macrocytic anaemia)
• Body weight at each clinic visit

What to tell your prescriber:

• Gut symptoms that last beyond 8 weeks at a stable Ozempic dose
• Any blood sugar reading below 4.0 mmol/L
• Unplanned weight loss of more than 1 kg per week
• Signs of low B12 (numbness or tingling in your hands and feet)

You can take both medicines long-term. NICE does not set a time limit on either drug, as long as they keep working and you tolerate them.